Every 8-K that Ehealth Inc (EHTH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EHTH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EHTH filings page.
eHealth reported Q2 2026 results that reflect a strategic pullback in Medicare marketing and a shift toward deeper member engagement. Total revenue was $33.6 million, down 45% from $60.8 million a year earlier, driven by lower Medicare enrollment volume and reduced variable marketing spend outside major enrollment periods. Medicare segment revenue fell to $31.8 million from $58.1 million, and tail (net adjustment) revenue declined to $7.6 million from $17.8 million. GAAP net loss widened to $23.6 million versus $17.4 million, and adjusted EBITDA was ($21.8) million compared with ($14.1) million.
Cost actions and a new Lifetime Advisory model are reshaping the profile. Total operating costs and expenses decreased 27% to $61.0 million from $83.8 million, and operating cash flow improved sharply to ($5.0) million from ($41.2) million, a $36.2 million year-over-year improvement. Management targets more than $60.0 million in annual variable spend reductions and approximately $30.0 million in annual fixed cost savings. Ancillary product cross-sell rates doubled, and key member engagement metrics improved under the Lifetime Advisory model. Liquidity includes $101.0 million of cash, cash equivalents and marketable securities, and $1.0 billion of commissions receivable, up 10% year over year.
For full-year 2026, eHealth guides to total revenue of $405–$445 million, GAAP net income of $8–$25 million, adjusted EBITDA of $55–$75 million, and operating cash flow between ($10) million and $12 million, including expected positive net adjustment revenue of $16–$20 million. Management states it remains on track to achieve meaningful year-over-year improvements in operating cash flow and is building toward a return to growth in 2027.
eHealth, Inc. reported results of its 2026 annual stockholder meeting held on June 18, 2026. Stockholders approved an amendment and restatement of the Amended and Restated 2024 Equity Incentive Plan, increasing the maximum number of shares that may be issued under the plan by 1,300,000 shares.
As of the April 20, 2026 record date, holders of the company’s capital stock were entitled to 35,958,616 votes, and 29,916,794 votes were represented at the meeting, reflecting 83.19% of the total voting power. Stockholders also elected two Class II directors, ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, and approved on an advisory basis the compensation of named executive officers.
eHealth, Inc. reported first quarter 2026 results showing a strategic pullback in volume to improve profitability. Q1 2026 total revenue was $88.0 million, down 22% from $113.1 million a year earlier, as the company reduced Medicare marketing spend and focused on higher-return channels.
GAAP results shifted to a net loss of $4.7 million versus net income of $2.0 million, mainly due to $6.4 million in restructuring charges. Adjusted EBITDA was $9.0 million with a 10% margin, compared to $12.5 million and an 11% margin in Q1 2025. Total operating costs fell to $90.9 million, a 16% decrease, and non-GAAP operating costs declined 21%, supporting the company’s plan to cut full-year 2026 operating costs by about $90 million.
The Medicare segment’s gross margin improved to 41% from 34%, driven by a 3% increase in Medicare Advantage lifetime value per member and a 10% reduction in total acquisition cost per MA-equivalent approved member, raising the Medicare LTV-to-CAC ratio to 1.4x. Operating cash flow was $35.8 million, with cash and marketable securities of $110.8 million and commissions receivable of $1.0 billion as of March 31, 2026. eHealth reaffirmed full-year 2026 guidance, including total revenue of $405–$445 million, GAAP net income of $8–$25 million and adjusted EBITDA of $55–$75 million.
The company also announced that director Cesar Soriano will resign effective immediately before the June 18, 2026 annual meeting, citing focus on his CEO role at Confie Corporation, with no disagreement reported. Following his departure and the previously disclosed end of Andrea Brimmer’s term, the board plans to reduce its size from ten to eight members.
eHealth, Inc. announced that director Andrea C. Brimmer will not stand for re-election and will leave the Board when her current term ends at the 2026 annual meeting on June 18, 2026. The company stated that her decision does not reflect any disagreement over operations, policies, or practices.
Brimmer has served on the Board for nearly eight years, and both she and CEO Derrick Duke emphasized appreciation for her contributions and continued support for eHealth’s mission. eHealth describes itself as a leading independent online health insurance marketplace, offering access to over 180 health insurers across the United States.
eHealth, Inc. reported another year of improved profitability for 2025 while issuing a cautious outlook for 2026. Full-year 2025 revenue reached $554.0 million, up 4%, with GAAP net income rising to $40.0 million from $10.1 million and adjusted EBITDA increasing 40% to $97.3 million.
Fourth-quarter 2025 revenue was $326.2 million, up 4% year over year, while GAAP net income declined to $87.2 million from $97.5 million, mainly due to a higher effective tax rate. Q4 adjusted EBITDA improved 10% to $132.9 million, and the adjusted EBITDA margin increased to 41%.
The company ended 2025 with a $1.1 billion commissions receivable balance, up 12%, and enhanced liquidity by replacing a $70.0 million term loan with a $125.0 million asset-backed revolving credit facility maturing in 2028. For 2026, eHealth guides to revenue of $405–$445 million, GAAP net income of $8–$25 million, adjusted EBITDA of $55–$75 million, and operating cash flow between -$10 million and $12 million, prioritizing cash generation and margin over near-term growth.
eHealth, Inc. reported that its board approved amended and restated bylaws effective immediately. The changes adjust stockholder meeting notice deadlines to Eastern Time, set a timeline for the company to provide a director nominee questionnaire within five business days of request, define the term “principal competitor” for certain stockholder disclosure requirements, and clarify the company’s ability to maintain insurance for directors, officers, employees and agents under Delaware law, along with other ministerial updates.
The company also issued a press release on December 18, 2025 with preliminary operational results for its annual enrollment period and updated guidance ranges for the fiscal year ending December 31, 2025, describing its AEP performance as strong.
eHealth, Inc. (EHTH) furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025, and provided its financial condition as of that date. The press release is furnished as Exhibit 99.1, and supplemental investor materials are furnished as Exhibit 99.2.
The company also noted that it posts material information on its investor relations webpage and intends to use it for Regulation FD disclosures. The information in this report under Item 2.02 and the related exhibits is furnished, not filed, under the Exchange Act.
eHealth, Inc. entered into a Third Amendment to its Credit Agreement with Blue Torch Finance LLC and the existing lenders. The amendment extends the term loan’s maturity date from February 27, 2026 to January 29, 2027, giving the company additional time before repayment is due.
The filing states that other material terms of the original credit facility, including the outstanding principal amount of the term loan, remain unchanged. eHealth also issued a press release on October 7, 2025 announcing the amendment, which is furnished as an exhibit.
eHealth, Inc. reported changes to its Board of Directors. On September 17, 2025, Aaron Tolson resigned from the Board and from the Compensation, Nominating, and Government and Regulatory Affairs Committees. His resignation is stated not to result from any disagreement with the company.
The Board immediately appointed Todd Arden, a designee of H.I.G. under an existing investment agreement, to fill the vacancy as a Class I director with a term ending at the 2028 annual meeting. He also joined the same three committees. Arden received time-based restricted stock units valued at $150,000, vesting in three equal annual installments, and will receive pro rata portions of the standard cash retainers for Board and committee service.
On September 18, 2025, the Board expanded its size from nine to ten directors and appointed Derrick Duke as a Class I director, also serving until the 2028 annual meeting. The company notes there are no required related-party or family relationship disclosures for either Arden or Duke.
eHealth, Inc. (Nasdaq: EHTH) submitted a Form 8-K on 6 Aug 2025 to furnish, rather than file, its second-quarter 2025 results under Item 2.02.
Highlights
- Exhibit 99.1 contains the full press release covering financial performance for the three and six months ended 30 Jun 2025.
- Exhibit 99.2 provides accompanying conference-call slide materials; both are also available on the company’s investor-relations website.
- Because the data are “furnished,” they are excluded from liability under Exchange Act §18 and are not automatically incorporated into other SEC filings.
- No other material transactions, financial statements, or governance changes were disclosed; the filing is strictly a results announcement conduit.
eHealth (Nasdaq:EHTH) filed an 8-K disclosing two material governance items: an extension of Chief Executive Officer Fran Soistman’s tenure and the 2025 Annual Meeting voting results.
CEO Transition. The board has not yet appointed a successor, so Mr. Soistman will continue as CEO until the earlier of a successor’s start date or 30 Sep 2025 and then serve as executive advisor through 31 Dec 2025. In exchange, he will receive (i) a $1.0 million retention cash award payable on the first payroll date in Jan 2026, conditioned on service through the transition period, and (ii) an annual performance-based cash bonus tied to the 2025 executive bonus metrics. He will continue to draw his current base salary and vesting will proceed under existing equity awards; no severance will be owed when he relinquishes the CEO title.
Shareholder votes. Of the 34.5 million votes eligible, 72.3 % were represented. Stockholders re-elected three Class I directors, ratified Ernst & Young LLP, and approved the 2025 advisory say-on-pay. They also approved an amendment to the 2024 Equity Incentive Plan to add 1.5 million shares (≈5 % of outstanding common stock), expanding the company’s capacity to grant equity awards.
The filing enhances leadership stability but increases executive compensation expense and introduces potential dilution from the larger share pool.